ProCE Banner Activity

CME

Cancer Conversations™ in RCC: Improving Outcomes With Immunotherapy and Targeted Agents

Multimedia
Watch this interactive webcast of a live CCO webinar to gain expert perspectives on individualizing treatment for patients with RCC.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 18, 2021

Expiration: November 17, 2022

No longer available for credit.

Share

Faculty

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Brian I. Rini

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for medical and urologic oncologists and other healthcare professionals involved in the care of patients with RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select first-line ICI-based combination treatment for individual patients with advanced or metastatic RCC, taking into consideration available clinical evidence, expert recommendations, and patient preferences
  • Recommend treatment options for patients with pretreated advanced RCC through multiple lines of therapy that consider prior treatment history and patient comorbidities
  • Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC
  • Evaluate ongoing major clinical trials investigating novel therapeutic approaches in advanced or metastatic RCC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Calithera, Flatiron, Genentech, Infinity, Janssen, MEI, Merck, Pfizer, and Seattle Genetics.

Faculty Disclosure

Primary Author

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD, has disclosed that she has received funds for research support from Bayer and Pfizer and consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Dendreon, Exelixis, Johnson & Johnson, Merck, Novartis, and Pfizer.

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Brian Rini, MD, FASCO, has disclosed that he has received funds for research support from Aravive, Arrowhead, AVEO, Bristol-Myers Squibb, Eisai, Merck, and Pfizer; consulting fees from Aravive, Arrowhead, AVEO, Bristol-Myers Squibb, Eisai, Merck, Nikang, and Pfizer; and other financial or material support from Merck and Pfizer.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 18, 2021, through November 17, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate recent findings into the treatment of patients with RCC.